Anticipated $-0.49 EPS for Egalet Corporation (EGLT) as of May, 9

April 17, 2018 - By Georgina Andrews

Egalet Corporation (NASDAQ:EGLT) Corporate Logo
Big Money Sentiment decreased to 0.47 in 2017 Q4. It has change of 0.11, from 2017Q3’s 0.58. The ratio fall due to Egalet Corporation positioning: 13 sold and 17 reduced. 6 funds bought positions and 8 increased positions. Investors holded 20.27 million in 2017Q3 but now own 13.62 million shares or 32.80% less.
1.04 million are held by Msd Partners L P. Bridgeway Cap owns 74,400 shs. 978 are held by Wells Fargo And Mn. Alyeska Inv Group Lp holds 842,402 shs or 0.01% of its capital. Franklin Resource stated it has 0% in Egalet Corporation (NASDAQ:EGLT). Vanguard Grp Inc reported 1.28M shs. Goldman Sachs Gru holds 0% of its capital in Egalet Corporation (NASDAQ:EGLT) for 68,731 shs. New York-based Morgan Stanley has invested 0% in Egalet Corporation (NASDAQ:EGLT). Highbridge Capital Mngmt Ltd Liability holds 0.06% or 3.51M shs. Raymond James Financial Services invested in 16,884 shs. J Goldman And Ltd Partnership accumulated 100,000 shs. Bnp Paribas Arbitrage Sa holds 0% of its capital in Egalet Corporation (NASDAQ:EGLT) for 38 shs. Janney Montgomery Scott Ltd Llc reported 22,159 shs or 0% of all its holdings. Highland Cap Mgmt Limited Partnership accumulated 119,520 shs or 0.01% of the stock. Moreover, Two Sigma Secs Ltd has 0% invested in Egalet Corporation (NASDAQ:EGLT).

Egalet Corporation (NASDAQ:EGLT)’s earnings report is expected by WallStreet on May, 9, RTT reports. This year’s EPS analyst estimate is expected to be $-0.49. That is 51.96 % up compareed to $-1.02 EPS for last year. After $-0.27 EPS report last quarter, Wall Street now sees 81.48 % negative EPS growth of Egalet Corporation. On during the last trading session the stock decreased $0.0013 or 0.20%, reaching $0.642.Egalet Corporation has volume of 115,866 shares. Since April 17, 2017 EGLT has declined 87.31% and is downtrending. EGLT underperformed the S&P500 by 98.86%.

Egalet Corporation (NASDAQ:EGLT) Ratings Coverage

Total analysts of 3 have positions in Egalet Corp (NASDAQ:EGLT) as follows: 1 rated it a “Buy”, 0 with “Sell” and 2 with “Hold”. The positive are 33%. Since November 8, 2017 according to StockzIntelligence Inc Egalet Corp has 4 analyst reports. On Wednesday, November 8 the rating was maintained by Cantor Fitzgerald with “Buy”. On Wednesday, January 3 Stifel Nicolaus downgraded Egalet Corporation (NASDAQ:EGLT) to “Hold” rating. On Monday, March 12 the stock of Egalet Corporation (NASDAQ:EGLT) has “Buy” rating given by Cantor Fitzgerald. On Thursday, November 9 the firm earned “Hold” rating by Gabelli.

Egalet Corporation, a specialty pharmaceutical company, develops, makes, and commercializes treatments for patients with pain and other conditions.The company has $33.93 million market cap. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic moderate to severe pain where an opioid is appropriate; and ARYMO ER, an extended-release morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.Currently it has negative earnings. The firm is also developing Egalet-002, a Guardian Technology AD, ER, oral oxycodone formulation, which is in Phase III clinical trials for the same indication as ARYMO ER.

Egalet Corporation (NASDAQ:EGLT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.